C. R. Bard

EndoGastric Solutions, Inc.® Announces CEO Transition and $18M Financing to Expand Commercialization

Retrieved on: 
tisdag, december 6, 2022
General Health, Surgery, Medical Devices, Other Health, Health, Laborie, Boston Scientific, Business administration, Catherine Disher, Patient, Goizueta Business School, Heartburn, C. R. Bard, Enzyme inhibitor, Palliative care, Gastroesophageal reflux disease, Asthma, Chronic cough, Laborie (company), Marketing, Growth, Emory University, EGS, University, General partnership, Global Sales Law Project, University of Southern Indiana, Management, GERD

Most recently, he had served as CEO of DYSIS Medical since September 2018.

Key Points: 
  • Most recently, he had served as CEO of DYSIS Medical since September 2018.
  • Before joining DYSIS, Mr. Hammers served as the President and CEO of Cogentix Medical, which Laborie acquired in April 2018.
  • He was promoted to Chief Operating Officer before being named President and CEO in July 2016.
  • Join the conversation on Twitter: @GERDHelp , Facebook: GERDHelp , Instagram: GERDHelp , and LinkedIn: EndoGastric Solutions
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005180/en/

TEAMFund Releases 4th Annual Impact Report (Now at 50MM+ Patient Services)

Retrieved on: 
tisdag, oktober 25, 2022
Fund, Conference, AdvaMed, Annual report, Patient, C. R. Bard, Access, Organic, The, Partnership, Report, Partner (business rank), Health, CEO, Equity, COVID-19, Morgan Lewis, Pharmaceutical industry, Health insurance, Medtech

BOSTON, Oct. 25, 2022 /PRNewswire/ -- TEAMFund, a 501(c)(3) Public Charity and a For-Profit Impact Fund whose mission is to enhance patient access to medical technology in low-resource settings, announced at The AdvaMed MedTech Conference, the release of their fourth Annual Impact Report. Despite the continued global impact of the COVID-19 pandemic, their seven portfolio companies (Jana Care, Forus Health, Tricog Health, MediBuddy, EchoNous, Vezeeta, and Qure.ai), provided 18.3MM+ new patient services and contributed to the needs of 11.5MM+ new unique patients in FY 2021 alone.

Key Points: 
  • BOSTON, Oct. 25, 2022 /PRNewswire/ --TEAMFund, a 501(c)(3) Public Charity and a For-Profit Impact Fund whose mission is to enhance patient access to medical technology in low-resource settings, announced at The AdvaMed MedTech Conference, the release of their fourth Annual Impact Report.
  • A complete copy of the Report can be found here FY 2021 Annual Report and at www.teamfundhealth.org .
  • The Report also links to separate Impact Reports for each of the Fund's seven portfolio companies.
  • As another announcement, based on the success of their $30MM Fund I, TEAMFund reported that it will begin fundraising for Fund II, with a target of $150MM.

Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs

Retrieved on: 
tisdag, september 6, 2022
Science, Other Science, Biotechnology, Research, Oncology, General Health, Health, Clinical Trials, Cardiovascular disease, BTG, Becton, Dickinson and Company headquarters, Degenerative disease, C. R. Bard, Therapy, Boston Scientific, Vaccine, Regenerative medicine, Becton, ITI, LAMP, Infection, Senior, Intelligence, Neurology, Allergy, Immunomics, San Diego State University, Compliance, Leadership, FDA, Regulatory affairs, Company, Biotechnology, Allergan, History, Medtronic, Elective surgery, Lysosome-associated membrane glycoprotein, Pharmaceutical industry, Science, Biochemistry

Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs.

Key Points: 
  • Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs.
  • She succeeds Louise Peltier, Vice President of Regulatory Affairs, who retired on August 31, 2022.
  • I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison.
  • Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific).

Dentsply Sirona Appoints Simon Campion as Chief Executive Officer

Retrieved on: 
torsdag, augusti 25, 2022
Becton, Dickinson and Company headquarters, Dentsply Sirona, University, D, XRAY, High Integrity C++, Development, C. R. Bard, Bachelor of Engineering, Boston Scientific, Surgery, Solution, Internationalization, Medicine, Interim, Board, Simon, Â, Open University, Executive, Audit committee, Mechanical, BD, Dental care, Intervention, Acceleration, MBA, GLOBE, Health, Leadership, Nasdaq, BD (company), Doctor of Philosophy, Cook Group, University of Limerick, National university, Mechanical engineering, Growth, Acquisition, Patient, Management, Risk management, Engineering, Company

CHARLOTTE, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Dentsply Sirona Inc. (Dentsply Sirona or the Company) (Nasdaq: XRAY) today announced that Simon Campion has been appointed President and Chief Executive Officer and will join the Companys Board of Directors (Board), effective September 12, 2022.

Key Points: 
  • CHARLOTTE, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Dentsply Sirona Inc. (Dentsply Sirona or the Company) (Nasdaq: XRAY) today announced that Simon Campion has been appointed President and Chief Executive Officer and will join the Companys Board of Directors (Board), effective September 12, 2022.
  • He succeeds John Groetelaars, who has served as Interim Chief Executive Officer since April 2022.
  • Mr. Campion said, Its an honor to join Dentsply Sirona and have the opportunity to lead this great team.
  • Simon Campion previously served as Executive Vice President & President of the Interventional and Medical segments at BD (Becton, Dickinson and Company).

Enable Injections Enhances Board with Addition of John DeFord, Ph.D.

Retrieved on: 
torsdag, augusti 11, 2022
BDX, Multimedia, CEO, Technology, Growth, Leadership, Becton, Dickinson and Company headquarters, Board, Director, C. R. Bard, Becton, SC, Nordson Corporation, Purdue University, Quality of life, Doctor of Philosophy, BD, View, Therapy, Administration, Economics, NDSN, Board of directors, Enblend, Injection, NuVasive, Organization, Management, Pharmaceutical industry

CINCINNATI, Aug. 11, 2022 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a company developing and manufacturing the enFuse® platform of investigational wearable drug delivery systems, is pleased to announce the appointment of John DeFord, Ph.D. to the company's Board of Directors, effective July 29, 2022.

Key Points: 
  • New director, John DeFord, Ph.D., adds global medical technology experience to Enable Injections, strengthening its mission to lead drug delivery innovation worldwide.
  • CINCINNATI, Aug. 11, 2022 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a company developing and manufacturing the enFuseplatform of investigational wearable drug delivery systems, is pleased to announce the appointment of John DeFord, Ph.D.to the company's Board of Directors, effectiveJuly 29, 2022.
  • New director, John DeFord, Ph.D., adds global drug delivery innovation experience to Enable Injections.
  • "We are pleased to welcome Dr. DeFord as a new director to Enable's Board," said Mike Hooven, President and CEO of Enable Injections.

Sharon Luboff Joins Water Street Healthcare Partners

Retrieved on: 
tisdag, juli 19, 2022
Medtronic, Johnson & Johnson, Baxter International, Water Street Historic District (Torrington, Connecticut), Water, Multimedia, Growth, Investment, Industry, Water Street, Walgreen, C. R. Bard, Pharmaceutical industry, Retail, Management, Humana

CHICAGO, July 19, 2022 /PRNewswire/ -- Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, announced today that Sharon M. Luboff has joined the firm as an executive advisor. Highly regarded for leading premier businesses at C.R. Bard and Baxter Healthcare, Ms. Luboff will work with Water Street to identify opportunities to partner with founders, executives and corporations interested in growing their medical products companies.  

Key Points: 
  • CHICAGO, July 19, 2022 /PRNewswire/ -- Water Street Healthcare Partners , a strategic investor focused exclusively on the health care industry, announced today that Sharon M. Luboff has joined the firm as an executive advisor.
  • Bard and Baxter Healthcare, Ms. Luboff will work with Water Street to identify opportunities to partner with founders, executives and corporations interested in growing their medical products companies.
  • Her industry knowledge and strategic approach are an excellent fit with Water Street and will further our goal of building market-leading companies in key health care sectors," said Tim Dugan, managing partner, Water Street.
  • Water Street has completed nearly 150 investments and strategic acquisitions to build 38 market-leading healthcare companies in the past decade.

Boulder Creek Technologies Enters Exclusive Engineering and Manufacturing Agreement with Maratek

Retrieved on: 
tisdag, juni 14, 2022
Cannabis, Natural Resources, Manufacturing, Hemp, Engineering, Biomass, Research, Bonde, Partnership, Grumman F7F Tigercat, Environment, Boulder Creek, Vapor, C. R. Bard, Technology, Industry, Recycling, Engineering, Safety, Automation, Fine chemical, Drug, Cannabis, Amway

Cannabis and hemp extraction technology company Boulder Creek Technologies and Canadian-based engineering, manufacturing and technology company Maratek have entered into an exclusive relationship that will see Maratek manufacture, provide engineering services and scale Boulder Creek Technologies Vapor-Static Extraction systems.

Key Points: 
  • Cannabis and hemp extraction technology company Boulder Creek Technologies and Canadian-based engineering, manufacturing and technology company Maratek have entered into an exclusive relationship that will see Maratek manufacture, provide engineering services and scale Boulder Creek Technologies Vapor-Static Extraction systems.
  • With Maratek we have found a partner that has this same passion for the environment and botanical medicine, along with its strength and decades of experience in industrial system design, engineering, and manufacturing, said Boulder Creek Technologies CEO Rick Bonde.
  • Though Vapor-Static Extraction was created by Boulder Creek Technologies, Maratek is working collaboratively to help increase its presence in the industry.
  • Boulder Creek Technologies and Maratek began finalizing the partnership details in March during the 2022 NoCo Hemp Expo.

Pneuma Systems names Chairman of its Scientific Advisory Board

Retrieved on: 
tisdag, juni 7, 2022
Caregiver, C. R. Bard, Company, Intellectual property, Observation, MBA, STEM, Environment, Nursing, Multimedia, Center, Band, Coronavirus Scientific Advisory Board (Turkey), FDA, Patient, Pharmacotherapy, Industry, Engineering, Safety, Pharmaceutical industry, Management, Hospital, Medical device, Pneuma

PORTSMOUTH N.H., June 7, 2022 /PRNewswire/ -- Pneuma Systems Corporation (Pneuma), an emerging leader in the infusion therapy industry, today announced that it appointed John Toomey as Chairman of its Scientific Advisory Board.  

Key Points: 
  • PORTSMOUTH N.H., June 7, 2022 /PRNewswire/ -- Pneuma Systems Corporation (Pneuma), an emerging leader in the infusion therapy industry, today announced that it appointed John Toomey as Chairman of its Scientific Advisory Board.
  • Empowering Care: Pneuma removes obstacles in infusion therapy, allowing nurses to focus on their patients.
  • Pneuma Founder and CEO Jeffrey Carlisle notes, "John has the ideal background to lead our Scientific Advisory Board and guide the Company with the best strategies for regulatory affairs and intellectual property management.
  • Recently, Pneuma announced a multi-faceted business collaboration with West Pharmaceutical Services, Inc. allowing Pneuma to provide a novel closed-loop fluid flow control platform ( https://prn.to/3Mw8VEX ).

Global Hemostasis Diagnostic Devices and Equipment Market Report 2022: Analyzers, Coagulation Instrument, Hemostasis Instruments, Reagents and Kits - Analysis & Forecasts 2016-2021, 2021-2026F, 2031F - ResearchAndMarkets.com

Retrieved on: 
fredag, maj 20, 2022
Biotechnology, Health, Medical Devices, Hemostasis, Coagulation, Pfizer, Disease, Blood, Company, Incidence, Patient, American Heart Association, VCD, Code, CVD, Asia-Pacific, PDP, Title 21 of the Code of Federal Regulations, CSL, Johnson & Johnson, PMA, Bandage, Bleeding, Baxter International, Man, Hospital, Technology, Degenerative disease, Vascular closure device, Skin, Wound healing, Becton, Dickinson and Company headquarters, Collagen, Abbott Laboratories, Laboratory, Classification, Cardiovascular disease, Vasoconstriction, C. R. Bard, Medical device, Medical imaging

The hemostasis diagnostic devices and equipment market consists of sales of hemostasis diagnostic devices.

Key Points: 
  • The hemostasis diagnostic devices and equipment market consists of sales of hemostasis diagnostic devices.
  • The main products of hemostasis diagnostic devices and equipment are analyzers, coagulation instruments, other hemostasis instruments, and reagents and kits.
  • Global Hemostasis Diagnostic Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
    6.2.
  • Global Hemostasis Diagnostic Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Legal-Bay Pre-Settlement Funding Reports on Hernia Mesh Cases

Retrieved on: 
onsdag, april 20, 2022
Nerve Damage, CEO, Injury, Kugel, Atrium, LLC, Open-ended fund company, Drainage, C. R. Bard, Patient, Bellwether, Bloating, Surgeon, Mark (given name), HERE, Extrapyramidal system, Johnson & Johnson, Chronic pain, Ethicon Inc., Industry, Nausea, Time, Pharmaceutical industry, Tobacco, Bank, Insurance, COVID-19

JERSEY CITY, N.J., April 20, 2022 /PRNewswire/ -- Legal-Bay LLC, The Pre-settlement Funding Company, announced today that they are seeing an uptick in hernia mesh lawsuits, specifically the two most popular brands: Johnson & Johnson's Ethicon Physiomesh and Atrium Medical Corporation's C-Qur. Both devices are currently being recalled due to numerous patient complications.

Key Points: 
  • Chris Janish, CEO of Legal-Bay commented, "The hernia mesh litigation is one of the most multifaceted, involving many different manufacturers and products.
  • If you need a lawsuit loan from your hernia mesh lawsuit, please apply HERE or call toll-free at 877.571.0405.
  • There are thousands of hernia mesh cases waiting to be heard, and the dockets have been even further backlogged because of Covid closures.
  • If you haven't yet filed suit, Legal-Bay can put you in touch with an attorney who specializes in hernia mesh cases.